DoD Bone Marrow Failure, Investigator-Initiated Research Award

Active
Yes
Status
Posted
Published Date
June 7th, 2024
Close Date
October 9th, 2024
Total Funding
$2,440,000.00
Expected No. Awards
2
Opportunity No.
HT942524BMFRPIIRA

Agency

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has posted a grant opportunity titled "DoD Bone Marrow Failure, Investigator-Initiated Research Award". This grant aims to support research in the field of bone marrow failure and offers two funding levels with different intents. Funding Level 1 (FL1) is intended to support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY24 BMFRP Focus Areas. FL1 awards may involve translational and clinical research, including studies in animal models, research with human data and/or anatomical substances, and research with human subjects. However, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged. Funding Level 2 (FL2) is aimed at supporting Investigational New Drug (IND) application-enabling efforts. The BMFRP recognizes the challenges associated with advancing promising therapeutic agents from the laboratory to clinical evaluation. FL2 awards require empirical studies focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U.S. Food and Drug Administration (FDA). FL2 applications must address the FY24 BMFRP Focus Area of finding effective treatments and cures for bone marrow failure. The grant opportunity does not require cost sharing or matching and is open to unrestricted applicants. The total program funding is $2,440,000, and it is expected that two awards will be granted. The closing date for applications is October 9, 2024, and the archive date is November 8, 2024. For more information and assistance, interested applicants can contact the CDMRP Help Desk via phone at 301-682-5507 or email at help@eBRAP.org.

Description

The FY24 BMFRP Investigator-Initiated Research Award (IIRA) will offer two funding levels with different intent:Funding Level 1 (FL1): To support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY24 BMFRP Focus Areas. IIRA applications may involve translational and clinical research including studies in animal models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, FL1 awards may not be used to support a clinical trial. An application that proposes a correlative study should be associated with a clinical trial(s), and the proposed study should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or other impactful outcomes. Multidisciplinary collaborations are encouraged.Funding Level 2 (FL2): To support Investigational New Drug (IND) application-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U.S. Food and Drug Administration (FDA). At least one and no more than three lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. Library screening or drug optimization studies do not meet the intent of FL2. The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY24 BMFRP Focus Area, “Find effective BMF treatments and cures.”

Contact Information

Attachments
545 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

DoD Bone Marrow Failure, Idea Development Award
Dept. of the Army -- USAMRAA
The Department of the Army -- USAMRAA has posted a grant opportunity titled "DoD Bone Marrow Failure, Idea Development Award". This grant is in the category of Science and Technology and other Research and Development. The grant does not require cost sharing or matching. The total program funding is estimated to be $4,240,000, with an expected number of 5 awards to be given. The grant is open to unrestricted applicants. The purpose of the BMFRP Idea Development Award (IDA) is to support innovative ideas and high-impact approaches based on scientifically sound evidence to advance the understanding and cure of Bone Marrow Failure (BMF) diseases. This funding opportunity is specifically designed to support new ideas and research studies that have the potential to reveal new avenues of investigation. The proposed research should have a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed research approach. The grant encourages hypothesis-driven correlative studies associated with clinical trials that align with the innovative intent of this award mechanism. If proposing a correlative study, it should be associated with a clinical trial(s) and should contribute to the generation of new hypotheses or advance the understanding of disease biology, treatment mechanisms, or other innovative and impactful outcomes. It is important to note that funding to conduct the clinical trial itself is not included in this funding opportunity. This grant opportunity is open to both Established Investigators (EIs) and Early-Career Investigators (ECIs). ECIs will be assessed using different criteria for personnel during the review process. Regardless of career level, the proposed team should have a strong background in BMF disease research. For more information or assistance, you can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507. The opportunity to apply for this grant will close on October 9, 2024, and the archive date is set for November 8, 2024.
DoD Joint Warfighter Medical, Military Medical Research and Development Award
Dept. of the Army -- USAMRAA
The Department of the Army -- USAMRAA has posted a federal grant opportunity titled "DoD Joint Warfighter Medical, Military Medical Research and Development Award". This procurement contract falls under the category of Science and Technology and other Research and Development. The grant does not require cost sharing or matching. The estimated total program funding for this opportunity is $7,400,000, with an expected number of 3 awards to be granted. The purpose of this grant is to fund the continuation of previously DOD-funded research or development efforts that are relevant to the FY24 JWMRP Focus Areas. The aim is to accelerate and augment the development of medical products and healthcare solutions for active-duty Service Members, their Families, Veterans, and/or the American public. Collaboration with DOD organizations is encouraged, and applications/proposals from small businesses and partnerships with industry are also welcomed. The MMRDA mechanism supports a wide range of research projects, including late-stage preclinical studies, late-stage technology development efforts, technology demonstration, and translational research. Additionally, there is a Clinical Research or Clinical Trial Option available to support clinical research/observational studies, all phases of clinical trials/interventional studies, and correlative studies for the development of promising pharmaceutical or biologic candidates, medical devices, and technologies. Applicants are encouraged to collaborate with DOD organizations when it contributes to the success of the research effort. If any funds are designated for DOD laboratories or activities, they should be identified in the application/proposal through the submission of a "Suggested Intragovernmental/Intramural Budget Form," Attachment 15. Applicants are also required to submit additional relevant application/proposal materials if applying under the Clinical Research or Clinical Trial Option. The close date for this grant opportunity is August 29, 2024, and the archive date is September 28, 2024. For any inquiries or assistance, applicants can contact the CDMRP Help Desk via phone at 301-682-5507 or email at help@eBRAP.org.